dailyai.report

CEO Dario Amodei suggests AI will provide immediate utility in biotechnology despite widespread industry hype. He emphasizes practical gains over speculative breakthroughs. This approach focuses on incremental efficiency rather than sudden discovery. Practitioners should expect steady tool improvements rather than an overnight cure for complex diseases. The impact remains modest but consistent.